- The ATLANTIC trial of cancer drug durvalumab supports clinical activity, says AstraZeneca.

ATLANTIC investigated the efficacy and tolerability of durvalumab in patients who received at least two prior systemic treatment regimens including platinum-based chemotherapy, and who have limited options for further therapy.

An initial analysis supports durvalumab's clinical activity, with durable responses and an established safety profile in these difficult-to-treat patients.

Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: "As we have seen in other studies, durvalumab has demonstrated expected clinical activity and durable response in these heavily pre-treated patients. As previously communicated, the treatment and regulatory landscape in lung cancer is evolving. We now believe it is unlikely that ATLANTIC can be used for regulatory submission as a monotherapy, but we will make that determination following a full analysis of the data. Durvalumab is a cornerstone of our immuno-oncology portfolio with a fast advancing development programme focused primarily on novel combinations."

At 8:17am: [LON:AZN] AstraZeneca PLC share price was -5.75p at 4428.25p

Story provided by